Quick Facts: Therapeutic Domains

• Chronic Obstructive Pulmonary Disease (COPD): Used as an option for long-term management.
• Asthma: May support the relief of symptoms associated with bronchial conditions.
• Bronchitis: Used in the context of managing breathing difficulties.

What Dereflin Treats: Main Uses and Benefits

Dereflin (a brand containing etofylline and theophylline) is indicated for use in the management of specific respiratory conditions. It is used as an adjunctive treatment to help support patients experiencing breathing difficulties related to airflow obstruction in the lungs.

The medication is employed in the treatment regimen for Chronic Obstructive Pulmonary Disease (COPD), a common lung disease characterized by persistent respiratory symptoms and airflow limitation. Its use may support the improvement of airflow and help manage related symptoms such as coughing, wheezing, and the feeling of chest tightness.

Additionally, Dereflin is used for the long-term management of asthma symptoms. By supporting the relaxation of muscles surrounding the airways, it may help maintain a more open airway, potentially facilitating easier breathing for individuals with persistent asthma or chronic bronchitis. The therapeutic goal of administration is to support respiratory function and symptom relief in the context of these chronic conditions. Theophylline, one of the active components, has a narrow therapeutic index.

Regulatory References

1. Chronic Obstructive Pulmonary Disease (COPD)

Who Can and Cannot Use Dereflin?

Eligibility for Dereflin (Etofylline/Theophylline) is determined by official regulatory criteria, which define both absolute prohibitions and conditions that require restricted use due to risk.

Contraindicated Populations

Use is contraindicated in patients with a known history of hypersensitivity to theophylline, etofylline, or other xanthine derivatives. Absolute prohibition is also mandated for individuals with active peptic ulcer disease or certain forms of coronary artery disease where myocardial stimulation is deemed harmful.

Age and Comorbidity Restrictions

Pregnancy and Lactation

The medicine is classified as FDA Pregnancy Category C; use during pregnancy is conditional, requiring a determination that the benefit outweighs the potential risk. It is excreted into breast milk, and monitoring of the nursing infant is required.

Dereflin Interactions with other medicines and products

The interaction profile for Dereflin is established through detailed pharmacokinetic studies that classify its effect on drug metabolism and transport systems, which dictates specific requirements for co-administration. These regulatory requirements are structured into classifications that define the severity and clinical management of potential interactions.

Interaction Scope and Restrictions

Specific interacting medicines and timing-based rules are detailed in the full prescribing information, and these lists are based on compounds that have demonstrated clinically significant effects on the metabolism of Dereflin in controlled studies. The co-administration requirements include the need for therapeutic drug monitoring and potential dosage adjustments for certain narrow therapeutic index drugs.

Population-specific interaction notes, where documented, primarily address patients with severe renal or hepatic impairment, as altered organ function may independently affect drug clearance, thereby changing the clinical relevance of a pharmacokinetic interaction. All interaction-related restrictions are regulatory requirements intended to prevent alterations in drug efficacy or safety.

Receptor-Mediated Signaling Modulation

Dereflin acts within domains involving receptor- or enzyme-mediated signaling to influence the activity of specific transmitters or mediators. It initiates signaling sequences that modify early molecular steps, contributing to the attenuation of amplified signaling activity.

Targeted Pathway Adjustment

The compound interacts with mechanisms that modulate typically amplified or atypical processes by modulating key pathways associated with heightened physiological responses. This applied action promotes the establishment of a modulated state within targeted pathways, reducing the resulting effects of excessive mediator activity.

Regulating Feedback Cascades

Dereflin is relevant in cascades where multiple layers of pathway activation occur, influencing the modification of processes governed by distinct signaling patterns. It influences feedback regulation within these pathways, resulting in defined physiological adjustments downstream of the initial molecular interaction.

How to Use Dereflin

Dereflin (Etofylline + Theophylline) administration is governed by a precise protocol to ensure the active component, theophylline, maintains a specific concentration in the bloodstream. This approach requires adherence to specific routes, scheduling, and monitoring procedures.

Official Administration Guidelines

Required Procedural Structure

The protocol mandates Therapeutic Drug Monitoring (TDM), which involves the regular measurement of theophylline serum concentrations to guide the correct dosing level. Correct use is achieved through strict adherence to the prescribed frequency, the prohibition against altering the tablet form, and mandatory laboratory surveillance.

Research Evidence / Overview of Studies for Dereflin (Esomeprazole)

Evidence for Use in Acid Reflux Disease (GERD) and Esophageal Healing

This section summarizes the structure of the clinical research, including the Randomized Controlled Trials (RCTs) and systematic reviews that have evaluated its use in studies exploring how symptoms change over time and the maintenance of mucosal integrity.

Research exploring short-term changes in symptoms has involved numerous short-term Randomized Controlled Trials where patients with conditions characterized by acute or disruptive episodes of acid reflux were monitored. These studies primarily focused on outcomes related to healing of the esophageal lining (confirmed by internal examination) and patient-reported outcomes describing perceived discomfort. Measured outcomes of mucosal healing were reported in patients with confirmed erosive esophagitis over defined time intervals, typically four to eight weeks. What remains unclear is how the evidence compares consistently against all other similar PPIs, as comparative evidence is lacking for some outcomes, and subgroup findings are uncertain.

Evidence for Use in H. pylori Eradication Therapy

This area focuses on the evidence base for Dereflin when it is used as part of a multi-drug combination regimen to address H. pylori infection. Studies monitored the successful clearance of the bacteria from the digestive system. Studies reported measurements of H. pylori clearance in observed populations using the 10-to-14-day triple therapy regimen. However, certainty remains low regarding consistent eradication success across all global populations, as results apply only to the populations studied and eradication patterns may vary based on local antibiotic resistance levels.

Long-Term Studies and Durability of Response

Research exploring short-term symptom changes often transitions into long-term observational settings to evaluate the durability of findings. Research has explored the medicine’s use in maintenance therapy for conditions presenting with cycles of stability and flare-ups, such as the prevention of recurring erosive esophagitis. Findings describe patterns observed in the studies suggesting that the medication may be studied for maintaining the healed state of the esophagus for periods up to six months. Long-term effects are not fully established for continuous use extending beyond these periods.

Common questions about Dereflin (FAQ)

Q: What is the primary use of Dereflin?

According to official regulatory information, this medication is primarily indicated as a bronchodilator. It is used to help manage the symptoms of chronic obstructive pulmonary disease (COPD) and asthma by working to relax the muscles and widen the air passages in the lungs.

Q: What are the signs of a Dereflin overdose or toxic level?

The most significant signs linked to high blood concentrations (toxicity) can include severe symptoms like persistent vomiting and nausea, dizziness, seizures, and heart problems such as an increased heart rate (tachycardia) or irregular heartbeats (cardiac arrhythmias). Regulatory documents state that these signs may be linked to high concentrations, and if they occur, patients should seek immediate medical attention, as treatment may need to be stopped.

Q: What should I do if I miss a dose?

Official patient information indicates that if a person recalls a missed dose, it may be taken immediately. However, if it is already close to the time for the next scheduled dose, the missed dose should generally be skipped to continue the regular dosing schedule. Product information cautions against taking a double dose to compensate for a missed dose.

Q: Are there any dietary restrictions I need to follow while taking this medication?

Official product information suggests that avoiding or limiting the consumption of large quantities of food and drinks high in caffeine may be necessary. This includes items such as coffee, tea, cola, and chocolate, as they may increase the risk of experiencing side effects from this medicine.

Q: Is Dereflin safe to use with antacids like Tums?

Official information regarding the immediate-release form of the active ingredient suggests that taking it at the same time as antacids does not usually cause significant changes to how the body absorbs the drug. Consultation with a healthcare professional is recommended regarding the use of specific over-the-counter products.

Q: How should I store the oral tablets and the intravenous (IV) form?

Official storage guidelines state that oral tablets must be kept at a controlled room temperature, typically between 20 C to 25 C, and they must be protected from moisture. The powdered form used for intravenous injection must never be frozen. The specific stability period and conditions for the IV solution after it is mixed are detailed on the product label.

Q: How is the dose for older adults determined?

Regulatory documents indicate that drug clearance may be slower in adults over the age of 60, which increases their risk of side effects. For this reason, the dose often needs to be lower and is guided by close blood concentration monitoring. Dosage is often adjusted and closely monitored to help keep the amount of medicine in the bloodstream within the defined therapeutic range.

Q: What is the brand name for Dereflin?

While the name Dereflin is used to refer to this specific combination of active ingredients, official drug registries list it under various brand names across different countries, such as Deriphyllin. The specific brand name used in a region should be confirmed with a pharmacist or prescribing doctor.

Dereflin must be stored strictly according to the conditions defined in the official regulatory labeling to maintain stability. The oral forms should be kept at a controlled room temperature, 20 C to 25 C (68 F to 77 F). The medicine must be protected from moisture and remain in its original, tightly closed container. The powder for injection must not be frozen. Once reconstituted, the intravenous solution has a limited stability period and must be used within the time specified on the label (e.g., 6 to 12 hours). For safety, the medicine must be stored out of the sight and reach of children. Unused or expired Dereflin should be disposed of via a drug take-back program when available, or by mixing it with an undesirable substance and discarding it in the trash, following official government guidance.